“…Similar results were found in the study by Saib et al and Abrieu-Lacaille et al, who used the same ablation protocol associated with micromonovision in the nondominant eye. 11,13 The advantage of micromonovision was also described by Schlote and Heuberger who used it in their series of 39 eyes a target refraction of À0.25 D on the nondominant eye associated using bilateral SUPRACOR; the monocular UDVA was 20/25 or greater in 77% of eyes and monocular UNVA of Jaeger 2 or greater in 87.2% of eyes after a followup period of 1 year. However, in some cases, presbyLASIK is contraindicated, and only presbyPRK in presbyopic hyperopic eyes can be offered to these patients who do not wish to undergo endoocular surgery.…”
Section: Discussionmentioning
confidence: 91%
“…The effectiveness of the SU-PRACOR algorithm for the treatment of hyperopic presbyopia has already been described in the literature. [8][9][10][11][12][13][14] Ryan and O'Keefe were the first to report their experience with SUPRACOR in 46 eyes of 23 patients who had undergone bilateral presbyLASIK and a follow-up period of 6 months. 8 At the end of the follow-up, the binocular far visual acuity without correction was 0.07 ± 0.12 logMAR with 78% of patients who had binocular UDVA of 20/25 or greater and 48% of patients with UDVA equal to 20/20; 73.9% of patients had binocular UNVA of Jaeger 2 or greater.…”
Section: Discussionmentioning
confidence: 99%
“…Similar results were found in the study by Saib et al and Abrieu-Lacaille et al, who used the same ablation protocol associated with micromonovision in the nondominant eye. 11,13…”
PresbyPRK and presbyLASIK are comparable in efficacy, stability, predictability, and safety at 12 months postoperatively. PresbyPRK is a good alternative when presbyLASIK is contraindicated.
“…Similar results were found in the study by Saib et al and Abrieu-Lacaille et al, who used the same ablation protocol associated with micromonovision in the nondominant eye. 11,13 The advantage of micromonovision was also described by Schlote and Heuberger who used it in their series of 39 eyes a target refraction of À0.25 D on the nondominant eye associated using bilateral SUPRACOR; the monocular UDVA was 20/25 or greater in 77% of eyes and monocular UNVA of Jaeger 2 or greater in 87.2% of eyes after a followup period of 1 year. However, in some cases, presbyLASIK is contraindicated, and only presbyPRK in presbyopic hyperopic eyes can be offered to these patients who do not wish to undergo endoocular surgery.…”
Section: Discussionmentioning
confidence: 91%
“…The effectiveness of the SU-PRACOR algorithm for the treatment of hyperopic presbyopia has already been described in the literature. [8][9][10][11][12][13][14] Ryan and O'Keefe were the first to report their experience with SUPRACOR in 46 eyes of 23 patients who had undergone bilateral presbyLASIK and a follow-up period of 6 months. 8 At the end of the follow-up, the binocular far visual acuity without correction was 0.07 ± 0.12 logMAR with 78% of patients who had binocular UDVA of 20/25 or greater and 48% of patients with UDVA equal to 20/20; 73.9% of patients had binocular UNVA of Jaeger 2 or greater.…”
Section: Discussionmentioning
confidence: 99%
“…Similar results were found in the study by Saib et al and Abrieu-Lacaille et al, who used the same ablation protocol associated with micromonovision in the nondominant eye. 11,13…”
PresbyPRK and presbyLASIK are comparable in efficacy, stability, predictability, and safety at 12 months postoperatively. PresbyPRK is a good alternative when presbyLASIK is contraindicated.
“…Our data are consistent with studies on the Supracor algorithm in hyperopic populations. [20][21][22][23][24][25][26][27] At 12 months postoperatively, Saib et al observed a binocular UDVA of 20/25 or better in 100% of patients and a binocular UNVA of Jaeger 2 or better in 94.7% of patients. 20 Ang et al found that 93% of patients had a binocular UDVA of 20/25 or better, and 85% of patients had a binocular UNVA of Jaeger 2 or better at 6 months after the procedure.…”
Section: Discussionmentioning
confidence: 99%
“…Studies in hyperopic populations have confirmed the safety profile of Supracor, with relatively rare serious complications and revision surgeries. 20,21,24 In addition, surgical retreatment appeared to be less frequent than that for monovision. 7 Indeed, in a study of 82 eyes treated with monovision LASIK, 28% required revision surgery to improve a nonoptimal result.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.